Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom

BACKGROUND: The prognosis for hepatocellular carcinoma (HCC) is dependent upon tumour stage, performance status (PS), severity of underlying liver disease, and the availability of appropriate therapies. The unavailability of sorafenib may have a significantly adverse effect on the prognosis of UK pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, D H, Hussain, S A, Smith, A J, Hargreaves, S, Ma, Y T, Hull, D, Johnson, P J, Ross, P J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749577/
https://www.ncbi.nlm.nih.gov/pubmed/23880824
http://dx.doi.org/10.1038/bjc.2013.410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749577/
https://www.ncbi.nlm.nih.gov/pubmed/23880824
http://dx.doi.org/10.1038/bjc.2013.410

Ejemplares similares